Advanced

ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer

Borg, Åke LU ; Baldetorp, Bo LU ; Fernö, Mårten LU ; Killander, Dick LU ; Olsson, Håkan LU ; Ryden, Stefan and Sigurdsson, Helgi (1994) In Cancer Letters 81(2). p.137-144
Abstract
Amplification and overexpression of the ERBB2 (HER-2/neu) oncogene has been implicated as contributing to the development of human breast cancer, and as a predictor of poor survival. In the present non-randomized study of 871 primary invasive breast tumours, ERBB2 activation was significantly correlated to a shorter disease-free and overall survival in the subgroup of patients receiving adjuvant tamoxifen therapy, but not in the untreated group. Further subcategorization demonstrated the relationship to poor prognosis to be confined to lymph node positive and steroid receptor-positive tumours. We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence... (More)
Amplification and overexpression of the ERBB2 (HER-2/neu) oncogene has been implicated as contributing to the development of human breast cancer, and as a predictor of poor survival. In the present non-randomized study of 871 primary invasive breast tumours, ERBB2 activation was significantly correlated to a shorter disease-free and overall survival in the subgroup of patients receiving adjuvant tamoxifen therapy, but not in the untreated group. Further subcategorization demonstrated the relationship to poor prognosis to be confined to lymph node positive and steroid receptor-positive tumours. We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence showing an oestrogen receptor dependent up-regulation of ERBB2 expression upon tamoxifen administration, possibly even growth stimulated by the drug. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
ERBB2, HER-2/neu, Gene amplification, Breast cancer, Adjuvant tamoxifen, Therapy resistance
in
Cancer Letters
volume
81
issue
2
pages
137 - 144
publisher
Elsevier
external identifiers
  • pmid:7912163
  • scopus:0028360192
ISSN
1872-7980
DOI
10.1016/0304-3835(94)90194-5
language
English
LU publication?
yes
id
2fef2982-b3de-4e06-beae-97042cee2e70 (old id 1107793)
date added to LUP
2008-07-22 15:27:46
date last changed
2017-02-12 04:08:57
@article{2fef2982-b3de-4e06-beae-97042cee2e70,
  abstract     = {Amplification and overexpression of the ERBB2 (HER-2/neu) oncogene has been implicated as contributing to the development of human breast cancer, and as a predictor of poor survival. In the present non-randomized study of 871 primary invasive breast tumours, ERBB2 activation was significantly correlated to a shorter disease-free and overall survival in the subgroup of patients receiving adjuvant tamoxifen therapy, but not in the untreated group. Further subcategorization demonstrated the relationship to poor prognosis to be confined to lymph node positive and steroid receptor-positive tumours. We suggest that steroid receptor and ERBB2-positive breast tumours are resistant to tamoxifen therapy and, supported by experimental evidence showing an oestrogen receptor dependent up-regulation of ERBB2 expression upon tamoxifen administration, possibly even growth stimulated by the drug.},
  author       = {Borg, Åke and Baldetorp, Bo and Fernö, Mårten and Killander, Dick and Olsson, Håkan and Ryden, Stefan and Sigurdsson, Helgi},
  issn         = {1872-7980},
  keyword      = {ERBB2,HER-2/neu,Gene amplification,Breast cancer,Adjuvant tamoxifen,Therapy resistance},
  language     = {eng},
  number       = {2},
  pages        = {137--144},
  publisher    = {Elsevier},
  series       = {Cancer Letters},
  title        = {ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer},
  url          = {http://dx.doi.org/10.1016/0304-3835(94)90194-5},
  volume       = {81},
  year         = {1994},
}